



AlMoosa Health Company

Fiscal Period: 2024 Q1

September 22nd, 2024

■ Company Description

| | |
|------------------------|---------------------|
| ISIN | - |
| Nation | Saudi Arabia |
| Primary Exchange | - |
| Core Business Activity | Healthcare Services |

Almoosa Health Company (the "Company") (formerly "Almoosa Specialist Hospital Company") is a closed joint stock company registered in the Kingdom of Saudi Arabia under Commercial Registration number 2252022248 dated 6 Shaban 1435H (4 June 2014). The principal activities of the Company are to act as a private healthcare provider, storing medical items and selling medicine, cosmetics and disposable medical items. The Company's registered office is in Al-Ahsa, Kingdom of Saudi Arabia.

■ Business Screening

Non-Permissible Income:

According to the fiscal period ending 31 March 2024 – as shown below - total Income reported is SAR 280,313,400.

| | Note | 31 March 2024 (Unaudited) | 31 March 2023 (Unaudited) |
|--|------|---------------------------------|---------------------------------|
| Revenue | 9 | 277,157,190 | 232,664,215 |
| Cost of revenues | | (198,612,967) | (162,860,555) |
| Gross profit | | 78,544,223 | 69,803,660 |
| Other income | | 2,864,792 | 2,986,333 |
| Selling and distribution expenses | | (5,953,020) | (4,213,090) |
| General and administrative expenses | | (40,605,409) | (37,034,734) |
| Provision for impairment loss on accounts receivable | | (1,344,029) | (869,012) |
| Gain on derivative financial instruments | | 3,138 | 2,918,264 |
| Operating profit | | 33,509,695 | 33,591,421 |
| Finance cost | | (17,471,258) | (6,593,989) |
| Share of profit of equity-accounted investee | | 288,280 | - |
| Profit before zakat | | 16,326,717 | 26,997,432 |
| Zakat expense | | (2,600,000) | (907,567) |
| Profit for the year | | 13,726,717 | 26,089,865 |

As shown below – the company is engaged in providing healthcare services, which is compliant with shariah law.

The principal activities of the Company are to act as a private healthcare provider, storing medical items and selling medicine, cosmetics and disposable medical items. The Company's registered office is in Al-Ahsa, Kingdom of Saudi Arabia.

As per note 4 for the period ending 31 March 2024 - as shown below – the equity-accounted investee represents investment in the unlisted company "Oryx Isotopes Company" with a shariah compliant business activity. Accordingly, total investment income from unlisted company with shariah complaint business activity is SAR 288,280.

4. EQUITY-ACCOUNTED INVESTEE

The investment in equity-accounted investee represents a 25% ownership in Oryx Isotopes Company ("the associate"), a Limited Liability Company registered on 13/1/1442H corresponding to 1 September 2020G in Dammam, Kingdom of Saudi Arabia with a share capital of SR 500,000. The principal activities of the Company are manufacturing of pharmaceuticals for human use and the production of radioactive isotopes.

As per our correspondence with the company on the 22nd of September 2024, the company confirmed that the derivative financial instruments are shariah complaint. Accordingly, income from derivative financial instruments of SAR 3,138 is shariah compliant.

Therefore:

- Total Non-Permissible Income = Zero
- Total Investment Income from Unlisted Company with Shariah Compliant Business Activity = 288,280
- Total Income = 280,313,400

■ Financial Screening

Debt structure:

According to the fiscal period ending 31 March 2024 – as shown below - total debt reported is SAR 1,242,114,172.

| | | |
|--|-----|----------------------|
| Non-current liabilities | | |
| Long term loans | 7 | 1,035,812,264 |
| Lease liabilities | | 2,243,222 |
| Employees' benefits | | 106,682,985 |
| Total non-current liabilities | | 1,144,738,471 |
| Current liabilities | | |
| Accounts payable | | 220,235,527 |
| Accruals and other current liabilities | | 45,504,223 |
| Derivative financial instruments | | 267,434 |
| Refund liabilities | 9.1 | 77,060,097 |
| Long term loans – current portion | 7 | 110,601,252 |
| Short term borrowings | | 90,000,000 |
| Lease liabilities – current portion | | 3,190,000 |
| Zakat payable | 8 | 6,230,266 |
| Total current liabilities | | 553,088,799 |
| Total liabilities | | 1,697,827,270 |

As per note 7 for the fiscal period ending 31 March 2024 – as shown below – Loans from ministry of finance represent interest-free shariah complaint loans.

| | | |
|---|--|---|
| 7. LONG TERM LOANS | | |
| | 31 March 2024 (Unaudited) | 31 December 2023 (Audited) |
| Current | | |
| Loans from commercial banks | 100,000,000 | 82,450,893 |
| Loans from Ministry of Finance | 2,843,067 | 2,843,067 |
| Accrued interest expense | 7,758,185 | 7,807,963 |
| | 110,601,252 | 93,101,923 |
| Non- current | | |
| Loans from commercial banks | 1,024,500,000 | 1,043,959,840 |
| Loans from Ministry of Finance | 14,215,331 | 14,215,330 |
| Less: deferred income on loan from MoF | (2,217,132) | (2,472,882) |
| Less: amortization of transaction cost | (685,935) | (749,464) |
| | 1,035,812,264 | 1,054,952,824 |
| Loans from Commercial Banks | | |
| The Company obtained loan facilities from various local commercial banks. These loans are secured by personal guarantees of Mr. Abdulaziz AlMoosa, Mr. Malik Abdulaziz AlMoosa and Malek Al-Moosa and mortgage of various parcels of land. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin. | | |
| Loans from Ministry of Finance | | |
| In 2010, the Company entered into a loan agreement for SR 42.6 million with Ministry of Finance to finance the construction of hospital building. The loan is repayable in equal annual instalments of SR 2.8 million each which commenced from 2015 and will continue up to 2030. The loan provided is interest free and is secured by mortgage of a parcel of land which is in the name of Mr. Abdulaziz AlMoosa. | | |

As per our correspondence with the company on the 22nd of September 2024, the company confirmed that loans from commercial banks, short-term borrowings, and derivative financial instruments are all shariah compliant.

Therefore:

- Total Loans = 1,242,114,172
- Total Lease = 5,433,222
- Shariah Compliant Loans = 1,236,680,950
- Conventional Loans = Zero

Investment Structure:

According to the fiscal period ending 31 March 2024 – as shown below - total cash and cash equivalents reported is SAR 8,210,558.

| | Note | 31 March 2024 (Unaudited) | 31 December 2023 (Audited) |
|--|------|---------------------------------|----------------------------------|
| ASSETS | | | |
| Non-current assets | | | |
| Property and equipment | 3 | 1,753,985,651 | 1,743,602,369 |
| Intangible assets | | 3,711,307 | 4,125,851 |
| Right-of-use assets | | 4,767,779 | 5,974,214 |
| Equity-accounted investee | 4 | 8,088,280 | - |
| Total non-current assets | | 1,770,553,017 | 1,753,702,434 |
| Current assets | | | |
| Inventories | | 65,267,754 | 59,374,202 |
| Accounts receivable | 5 | 462,036,396 | 446,538,649 |
| Advances, prepayments and other current assets | | 34,577,530 | 26,344,374 |
| Cash and cash equivalents | | 8,210,558 | 15,838,943 |
| Total current assets | | 570,092,238 | 548,096,168 |
| Total assets | | 2,340,645,255 | 2,301,798,602 |

As per our correspondence with the company on the 22nd of September 2024, the company confirmed that all cash and cash equivalents are non-interest bearing.

According to the fiscal period ending 31 March 2024 – as shown below - total investments reported is SAR 8,088,280.

| | Note | 31 March 2024 (Unaudited) | 31 December 2023 (Audited) |
|--|------|---------------------------------|----------------------------------|
| ASSETS | | | |
| Non-current assets | | | |
| Property and equipment | 3 | 1,753,985,651 | 1,743,602,369 |
| Intangible assets | | 3,711,307 | 4,125,851 |
| Right-of-use assets | | 4,767,779 | 5,974,214 |
| Equity-accounted investee | 4 | 8,088,280 | - |
| Total non-current assets | | 1,770,553,017 | 1,753,702,434 |
| Current assets | | | |
| Inventories | | 65,267,754 | 59,374,202 |
| Accounts receivable | 5 | 462,036,396 | 446,538,649 |
| Advances, prepayments and other current assets | | 34,577,530 | 26,344,374 |
| Cash and cash equivalents | | 8,210,558 | 15,838,943 |
| Total current assets | | 570,092,238 | 548,096,168 |
| Total assets | | 2,340,645,255 | 2,301,798,602 |

As per note 4 for the period ending 31 March 2024 - as shown below – the equity-accounted investee represents investment in the unlisted company "Oryx Isotopes Company" with a shariah compliant business activity.

4. EQUITY-ACCOUNTED INVESTEE

The investment in equity-accounted investee represents a 25% ownership in Oryx Isotopes Company ("the associate"), a Limited Liability Company registered on 13/1/1442H corresponding to 1 September 2020G in Dammam, Kingdom of Saudi Arabia with a share capital of SR 500,000. The principal activities of the Company are manufacturing of pharmaceuticals for human use and the production of radioactive isotopes.

Therefore:

Total Investments = 8,088,280

Total Conventional Investments = Zero

Note:

Kindly note that AlMoosa Health Company is considered Shariah compliant following the Shariah regulations adopted by most Islamic banks and financial institutions in the Saudi market.

AAOIFI
Mandates



Al-Rajhi
Mandates



Alinma
Mandates



Albilad
Mandates



SRB
Mandates



*Purification ratio per share for the investment income from unlisted company with a shariah compliant business activity of SAR 288,280 is 0.824%.

This research is for our clients only. This research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The research reports are published at irregular intervals based on clients' request or as appropriate in our analysts' judgment.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction especially where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Copyright 2006-2024 IdealRatings, Inc. No part of this material may be (i) copied, photocopied or duplicated in any form by any means (ii) used to create derived data or restructure investment product (iii) redistributed without the prior written consent of IdealRatings, Inc.

To learn more visit us at: www.idealratings.com